Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30286474 | 1.00 | LPL (0.41) | LPLLIPGIRAK4P2RX7MAPT | |
| SCHEMBL4211647 | 0.81 | LPL (0.40) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL17268323 | 0.79 | CCR1 (0.45) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL29562655 | 0.78 | LIPG (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL13576201 | 0.78 | LIPG (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL31631018 | 0.78 | LPL (0.39) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL30086173 | 0.78 | CYP3A4 (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL18342256 | 0.78 | LPL (0.39) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL201979 | 0.78 | CYP3A4 (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL710355 | 0.78 | LPL (0.42) | LPLLIPGIRAK4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025008059-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2024-09-10 | — | — | US | disclosed |
| CN-117659010-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111867581-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230090406-A1 | 6-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| WO-2011094290-A1 | PYRAZOLOPYRIMIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | NOVARTIS AG (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012661-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | LPL 2317/4885LIPG 3973/4885IRAK4 3226/4885 |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | CDK9, CDK19, CDK3 | LPL 4400/4885LIPG 4432/4885IRAK4 3242/4885 |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | LPL 589/4885LIPG 1492/4885IRAK4 4598/4885 |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | LPL 589/4885LIPG 1492/4885IRAK4 4598/4885 |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | LPL 2260/4885LIPG 1408/4885IRAK4 1446/4885 |
| US-20230090406-A1 | 6-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | LPL 4774/4885LIPG 3279/4885IRAK4 3053/4885 |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | LPL 4774/4885LIPG 3279/4885IRAK4 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.